TD Cowen downgraded Royalty Pharma (RPRX) to Hold from Buy without a price target after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX: